Sign in

    Karishma Raghuram

    Biopharma Equity Research Analyst at Goldman Sachs

    Karishma Raghuram is a Biopharma Equity Research Analyst at Goldman Sachs, specializing in the coverage of leading pharmaceutical companies including AbbVie (ABBV), Johnson & Johnson (JNJ), and Alkermes (ALKS). She delivers sector coverage within the U.S. large-cap biopharmaceutical space, contributing research used in investment decisions and industry forecasts, though specific performance data or rankings are not publicly available. Raghuram began her career with internships at firms such as Fox Entertainment, NASA, and CHOC Children's before joining Goldman Sachs, where she has held roles including Global Investment Research Summer Analyst and was promoted to full-time analyst in June 2023. She holds a Bachelor of Science in Statistics and Data Science from UCLA and brings experience in healthcare research and data-driven analysis, but public records do not indicate FINRA registration or securities licensing.

    Karishma Raghuram's questions to Alkermes (ALKS) leadership

    Karishma Raghuram's questions to Alkermes (ALKS) leadership • Q3 2024

    Question

    Karishma Raghuram, on for Chris Shibutani, asked about the decision to pursue the idiopathic hypersomnia (IH) indication for the orexin program despite potential negative implications from the Inflation Reduction Act (IRA) and the commercial opportunity needed to justify this move.

    Answer

    CEO Richard Pops explained the decision was multifaceted. He noted the low probability of the IRA remaining unchanged in nine years and the potential for Congress to amend the provision hurting rare disease patients. From a commercial standpoint, the significant size of the IH market (~40,000 patients) and its clinical adjacency to narcolepsy made the expansion compelling, as it significantly grows the addressable market for nine years at the same price point.

    Ask Fintool Equity Research AI

    Karishma Raghuram's questions to RVNC leadership

    Karishma Raghuram's questions to RVNC leadership • Q4 2023

    Question

    Asked for framing on the cervical dystonia opportunity, including product positioning with payers and the impact of the permanent J-code on the revenue ramp.

    Answer

    Mark Foley described cervical dystonia as a $340 million market where DAXXIFY's long duration addresses a key unmet need. For payers, the product is attractive due to potential cost savings from its pricing and dosing, which has led to strong early commercial coverage (>50% of lives). The launch will be measured as physicians titrate doses over time, but the J-code is in place, and early feedback is very positive, positioning it as a gateway to the broader therapeutics market.

    Ask Fintool Equity Research AI